Endocrine & hormone · target hub

NR2F6

Nuclear receptor subfamily 2 group F member 6 (NR2F6)

NR2F6 is a Nuclear receptor / transcriptional control on the endocrine & hormone axis. Transcription factor predominantly involved in transcriptional repression. Binds to promoter/enhancer response elements that contain the imperfect 5'-AGGTCA-3' direct or inverted repeats with various spacings which are also recognized by other nuclear hormone receptors. Involved … It is indexed under "Nuclear receptor superfamily (major members)" on our pathway page for antibodies, inhibitors, and assay guidance.

Back to pathway overviewSearch: NR2F6UniProt (P10588)

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of NR2F6.
  • For nuclear receptors pair ligands, co-regulators, and reporter assays; for membrane receptors note GPCR/RTK downstream and desensitization.
  • Verify antibody clone, phospho-site, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
LBD / AF2Ligand-binding or AF2 domain variants
HotspotHormone-dependent tumor hotspots (gene-specific)
Cofactor switchingAltered co-regulator recruitment

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for NR2F6

  • Reporter / ChIP: NR2F6 promoter-luciferase or ChIP-qPCR.
  • Ligand treatments: estrogen/androgen/progesterone/glucocorticoid as appropriate.
  • Co-regulators: SRC/p300 co-activator or co-repressor co-IP.
  • Tumor specimens: receptor IHC with mutation/amplification annotation.

NR2F6 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for NR2F6 studies (examples)

  • Tool lines: MCF-7, T47D, LNCaP, MDA-MB-231, HEK293T—screen by NR2F6 expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (NR0B1, NR0B2, THRA, THRB) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for NR2F6 Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for NR2F6 Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for NR2F6 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-NR2F6 for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous NR2F6 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

NR2F6NR2F6 antibodyNR2F6 ligand/agonisthormone/receptor antibody

NR2F6-related antibodies (keyword-biased)

Adds NR2F6 keyword bias atop the 内分泌和激素 antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

NR0B1NR0B2THRATHRBRARARARBRARGRXRA

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the endocrine & hormone hub for neighboring targets—cross-check PI3K, MAPK, RTK, and metabolism pages as needed.

Endocrine & hormone·PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Metabolism